NOT FOR DISTRIBUTION
Header cover image

Market Cap

Rp68.9t

Last Updated

2021/05/10 17:18 UTC

Data Sources

Company Financials +

Executive Summary

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. More Details


Snowflake Analysis

Excellent balance sheet with proven track record and pays a dividend.


Similar Companies

Share Price & News

How has Kalbe Farma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: KLBF is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: KLBF's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

0%

KLBF

1.3%

ID Pharmaceuticals

-0.5%

ID Market


1 Year Return

6.1%

KLBF

20.4%

ID Pharmaceuticals

22.3%

ID Market

Return vs Industry: KLBF underperformed the ID Pharmaceuticals industry which returned 20.4% over the past year.

Return vs Market: KLBF underperformed the ID Market which returned 22.3% over the past year.


Shareholder returns

KLBFIndustryMarket
7 Day0%1.3%-0.5%
30 Day-5.2%-3.8%-2.7%
90 Day-3.6%-9.1%-5.5%
1 Year8.1%6.1%22.7%20.4%26.3%22.3%
3 Year12.4%6.1%2.3%-3.3%2.3%-5.4%
5 Year23.1%13.1%32.9%20.3%34.1%17.8%

Long-Term Price Volatility Vs. Market

How volatile is Kalbe Farma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kalbe Farma undervalued compared to its fair value and its price relative to the market?

25.21x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: KLBF (IDR1470) is trading above our estimate of fair value (IDR938.74)

Significantly Below Fair Value: KLBF is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: KLBF is poor value based on its PE Ratio (25.2x) compared to the ID Pharmaceuticals industry average (25x).

PE vs Market: KLBF is poor value based on its PE Ratio (25.2x) compared to the ID market (22.4x).


Price to Earnings Growth Ratio

PEG Ratio: KLBF is poor value based on its PEG Ratio (3.4x)


Price to Book Ratio

PB vs Industry: KLBF is overvalued based on its PB Ratio (4x) compared to the ID Pharmaceuticals industry average (2.4x).


Future Growth

How is Kalbe Farma forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

7.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KLBF's forecast earnings growth (7.5% per year) is above the savings rate (7.2%).

Earnings vs Market: KLBF's earnings (7.5% per year) are forecast to grow slower than the ID market (21.4% per year).

High Growth Earnings: KLBF's earnings are forecast to grow, but not significantly.

Revenue vs Market: KLBF's revenue (6.5% per year) is forecast to grow slower than the ID market (10.7% per year).

High Growth Revenue: KLBF's revenue (6.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KLBF's Return on Equity is forecast to be low in 3 years time (16%).


Past Performance

How has Kalbe Farma performed over the past 5 years?

5.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: KLBF has high quality earnings.

Growing Profit Margin: KLBF's current net profit margins (11.8%) are higher than last year (11.1%).


Past Earnings Growth Analysis

Earnings Trend: KLBF's earnings have grown by 5% per year over the past 5 years.

Accelerating Growth: KLBF's earnings growth over the past year (9%) exceeds its 5-year average (5% per year).

Earnings vs Industry: KLBF earnings growth over the past year (9%) underperformed the Pharmaceuticals industry 9%.


Return on Equity

High ROE: KLBF's Return on Equity (15.3%) is considered low.


Financial Health

How is Kalbe Farma's financial position?


Financial Position Analysis

Short Term Liabilities: KLBF's short term assets (IDR13,075.3B) exceed its short term liabilities (IDR3,176.7B).

Long Term Liabilities: KLBF's short term assets (IDR13,075.3B) exceed its long term liabilities (IDR1,111.5B).


Debt to Equity History and Analysis

Debt Level: KLBF's debt to equity ratio (5.8%) is considered satisfactory.

Reducing Debt: KLBF's debt to equity ratio has increased from 3.6% to 5.8% over the past 5 years.

Debt Coverage: KLBF's debt is well covered by operating cash flow (395.6%).

Interest Coverage: KLBF earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Kalbe Farma current dividend yield, its reliability and sustainability?

1.77%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: KLBF's dividend (1.77%) is higher than the bottom 25% of dividend payers in the ID market (1.15%).

High Dividend: KLBF's dividend (1.77%) is low compared to the top 25% of dividend payers in the ID market (4.83%).


Stability and Growth of Payments

Stable Dividend: KLBF's dividend payments have been volatile in the past 10 years.

Growing Dividend: KLBF's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (44.6%), KLBF's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: KLBF's dividends in 3 years are forecast to be well covered by earnings (49.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.6yrs

Average management tenure


CEO

- Vidjongtius (56 yo)

3.92yrs

Tenure

Mr. Vidjongtius has been President Director of PT Kalbe Farma Tbk. since June 5, 2017. He served as Corporate Secretary of PT. Kalbe Farma Tbk. since March 28, 2008 until June 14, 2017. Mr. Vidjongtius ser...


Leadership Team

Experienced Management: KLBF's management team is seasoned and experienced (7.6 years average tenure).


Board Members

Experienced Board: KLBF's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Kalbe Farma Tbk.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PT Kalbe Farma Tbk.
  • Ticker: KLBF
  • Exchange: IDX
  • Founded: 1966
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: Rp68.903t
  • Shares outstanding: 46.87b
  • Website: https://www.kalbe.co.id

Number of Employees


Location

  • PT Kalbe Farma Tbk.
  • Gedung KALBE
  • Jl. Let. Jend. Suprapto Kav. 4
  • Jakarta
  • Jakarta Raya
  • 10510
  • Indonesia

Listings


Biography

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. It operates in four divisions: Prescription Pharmaceuticals, Consumer Health...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/10 17:18
End of Day Share Price2021/05/10 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.